Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosbretabulin + paclitaxel + carboplatin
- Development stage
- Unknown
- Lead developer
- OXiGENE
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Fosbretabulin + paclitaxel + carboplatin is a combination regimen investigated primarily for the treatment of anaplastic thyroid cancer (ATC), a rare and aggressive malignancy. Fosbretabulin, also known as combretastatin A-4 phosphate (CA4P), is a vascular-disrupting agent that targets tumor blood vessels by destabilizing microtubules, leading to central necrosis of tumors. It acts as a prodrug and is converted in vivo to its active form, combretastatin A-4[7]. Paclitaxel and carboplatin are established chemotherapeutic agents that inhibit cell division by interfering with microtubule function (paclitaxel) and DNA crosslinking (carboplatin)[2]. The combination has been evaluated in clinical trials for ATC, where it was generally well tolerated but did not show statistically significant improvement in overall survival compared to chemotherapy alone[1][5]. Fosbretabulin was developed by Oxigene.
- Other names
- fosbretabulin disodiumfosbretabulin tromethamine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on fosbretabulin + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosbretabulin + paclitaxel + carboplatin.